New function and application of amarogentin for treating pulmonary arterial hypertension

A kind of technology of pulmonary arterial hypertension and gentioside, which is applied in the application field of preparing pulmonary arterial hypertension prevention and treatment medicine, and can solve the problems of not finding gentioside report and the like
CN103622985AInactive Publication Date: 2014-03-12FOURTH MILITARY MEDICAL UNIVERSITY
3 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Current Assignee / Owner
FOURTH MILITARY MEDICAL UNIVERSITY
Publication Date
2014-03-12
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a new function of amarogentin for preventing or treating pulmonary arterial hypertension, and belongs to the technical field of pharmacological action of a component. It is discovered that the amarogentin has an effect of obviously relieving myocardial hypertrophy, myocardial edema, pulmonary arteriolar wall thickening and stenosis caused by hypoxic pulmonary hypertension. Therefore, the amarogentin can be used for preparing a medicine for preventing and treating related cardiovascular diseases caused by the pulmonary arterial hypertension. The medicine can be prepared into tablet, capsule, granule, pill, powder, injection, emulsion or other pharmaceutically acceptable dosage forms.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the new action of gentioside in the treatment of pulmonary arterial hypertension and its application in the preparation of medicines for the prevention and treatment of pulmonary arterial hypertension, belonging to the technical field of pharmacological action of compounds. Background technique

[0002] Pulmonary Arterial Hypertension (PAH) is a kind of extremely malignant progressive disease characterized by progressive increase of pulmonary vascular resistance, eventually leading to right heart failure and even death. In the latest evidence-based clinical practice guidelines for the diagnosis and treatment of pulmonary arterial hypertension issued by the American College of Chest Physicians (ACCP), it is defined as mean pulmonary arterial pressure β‰₯ 25 mmHg, capillary pressure or left atrial pressure ≀ 15 mmHg. PAH is divided into two types: primary (PPH) and secondary (SPH). Clinically, the main manifestations are exertional...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More